The role of angiogenesis in hepatocellular carcinoma

MA Morse, W Sun, R Kim, AR He, PB Abada… - Clinical Cancer …, 2019 - aacrjournals.org
Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is
the second leading cause of cancer-related deaths worldwide. The hypervascular nature of …

[HTML][HTML] Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective

SJ Modi, VM Kulkarni - Medicine in Drug Discovery, 2019 - Elsevier
New blood vessels formation from the existing vasculature is called angiogenesis. It is an
essential physiological process for the growth of cells, tissue repair, wound healing, and …

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

V Thatikonda, H Lyu, S Jurado, K Kostyrko, CA Bristow… - Nature Cancer, 2024 - nature.com
Combination approaches are needed to strengthen and extend the clinical response to
KRASG12C inhibitors (KRASG12Ci). Here, we assessed the antitumor responses of …

Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis

G Marcelin, ALM Silveira, LB Martins… - The Journal of clinical …, 2019 - jci.org
Obesity originates from an imbalance between caloric intake and energy expenditure that
promotes adipose tissue expansion, which is necessary to buffer nutrient excess. Patients …

Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor

Y Zhao, AA Adjei - The oncologist, 2015 - academic.oup.com
Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …

Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial

RP Frantz, VV McLaughlin, S Sahay… - The Lancet …, 2024 - thelancet.com
Background Morbidity and mortality in pulmonary arterial hypertension (PAH) remain high.
Activation of platelet-derived growth factor receptor, colony stimulating factor 1 receptor, and …

Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review

S Yang, J Zhao, X Sun - Drug design, development and therapy, 2016 - Taylor & Francis
As a progressive chronic disease, age-related macular degeneration (AMD) is the leading
cause of irreversible vision impairment worldwide. Experimental and clinical evidence has …

Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation

R Nazarian, H Shi, QI Wang, X Kong, RC Koya, H Lee… - Nature, 2010 - nature.com
Abstract Activating B-RAF (V600E)(also known as BRAF) kinase mutations occur in∼ 7% of
human malignancies and∼ 60% of melanomas. Early clinical experience with a novel class …

Pulp-dentin regeneration: current approaches and challenges

C Jung, S Kim, T Sun, YB Cho… - Journal of tissue …, 2019 - journals.sagepub.com
Regenerative endodontic procedures for immature permanent teeth with apical periodontitis
confer biological advantages such as tooth homeostasis, enhanced immune defense …

Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension

A Galkin, R Sitapara, B Clemons… - European …, 2022 - publications.ersnet.org
Background Signalling through platelet-derived growth factor receptor (PDGFR), colony-
stimulating factor 1 receptor (CSF1R) and mast/stem cell growth factor receptor kit (c-KIT) …